Top Quality CAS 28860-95-9 Carbidopa Powder Carbidopa

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-carbidopa
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Carbidopa
• Name: Carbidopa Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: 99%
• Specific: COA
• Test Method: HPLC, UV
• CAS: 38821-49-7
• Mf: C10h16n2o5
• MW: 244.24400
• Boiling Point: 528.7oc at 760 Mmhg
• Stability: Stable
• Shelf Life: Shelf Life
• Density: 1.42 g/cm3
• Transport Package: Negotiable
• Specification: negotiable
• Trademark: QS
• Origin: Xian
• Production Capacity: 500 Kg/Month

Product Description

Top Quality CAS 28860-95-9 carbidopa powder carbidopa

Product Description

Product Details

Product name	Carbidopa
Cas number	38821-49-7
Apperance	White powder
MF	C10H16N2O5
MW	244.24400

Carbidopa/levodopa is a peripheral dopamine decarboxylase inhibitor, which is not easy to enter the center, so it only inhibits the conversion of peripheral levodopa into dopamine, which increases the circulating levodopa content by 5 to 10 times. When combined with levodopa, it can not only reduce the peripheral cardiovascular adverse reactions of levodopa, but also reduce the dosage of levodopa. Levodopa combined with carbidopa can improve the light activity of cone and rod cells, improve the lateral inhibition function of photoreceptors, and wake up the sensitive period of visual plastic. It can pass through the placenta and can be secreted from the milk. About 50% to 60% of the protoplasm or metabolites are excreted in the urine.

Application&Function

indication
1: It is suitable for spontaneous Parkinson's disease, but the effect is poor in advanced severe patients. 2: The treatment of monocular amblyopia is better, especially for anisometropic monocular amblyopia and amblyopia with amblyopia as the central fixation.
Adverse reaction
It is rarely used alone. When combined with levodopa, nausea and vomiting can occur. In addition, the adverse reactions caused by levodopa, such as abnormal involuntary motor disorders, tend to occur earlier. It can often cause mental depression, involuntary movements of the face, tongue, upper limbs and hands.
Matters needing attention
Users of monoamine oxidase inhibitors must stop using this drug for at least 2 weeks. If you have been treated with levodopa, you must stop levodopa for 8 to 12 hours before using this product. The common adverse reaction was abnormal involuntary movement. Patients with osteoporosis should slowly return to normal activities to reduce the risk of fracture. Blood routine, liver and kidney function and electrocardiogram should be checked during medication

Specification

About US